Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market
02 déc. 2021 16h45 HE | Saniona AB
PRESS RELEASE December 2, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the Chairman and the CEO, as well as additional...
Sanionas styrelseordförande J. Donald deBethizy, VD Rami Levin och andra styrelseledamöter och ledande befattningshavare förvärvar aktier i ordinarie börshandel
02 déc. 2021 16h45 HE | Saniona AB
PRESSMEDDELANDE 2 december 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att styrelsens ordförande, VD och andra...
Report from Incubate Policy Lab and Charles River Associates Finds Price Controls Would Decrease Investment in Critical Therapeutic Areas
18 nov. 2021 17h08 HE | Incubate
Washington, D.C., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Today, Incubate Policy Lab and Charles River Associates published a report detailing how investment into therapies for rare diseases and oncology...
Saniona publishes its interim report for the third quarter of 2021
18 nov. 2021 02h00 HE | Saniona AB
PRESS RELEASE November 18, 2021 Three Months Ended September 30, 2021 (2020) Revenue was SEK 2.3 M (2.2 M)Operating loss was SEK -88.2 M (-37.3 M)Net loss was SEK -93.7 M (-48.3 M)Basic loss per...
Saniona publicerar sin delårsrapport för det tredje kvartalet 2021
18 nov. 2021 02h00 HE | Saniona AB
PRESSMEDDELANDE 18 november 18, 2021 Jul - sep 2021 (jul - sep 2020) Intäkter uppgick till 2,3 MSEK (2,2)Rörelseresultat uppgick till -88,2 MSEK (-37,3)Periodens resultat uppgick till -93,7 MSEK...
Saniona inleder klinisk studie i Fas 2b med Tesomet för hypotalamisk fetma
17 nov. 2021 02h00 HE | Saniona AB
PRESSMEDDELANDE 17 november 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, tillkännager idag starten för en klinisk studie i Fas 2b...
Saniona Initiates Phase 2b Clinical Trial of Tesomet for Hypothalamic Obesity
17 nov. 2021 02h00 HE | Saniona AB
PRESS RELEASE November 17, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in...
Imara-Logo-Color-RGB.jpg
Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia
16 nov. 2021 07h00 HE | Imara, Inc.
Positive trend observed in transfusion-dependent subjects treated with higher dose tovinontrine for reduced transfusion burden Tovinontrine was generally well-tolerated in this patient population ...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
15 nov. 2021 16h15 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Third Quarter 2021 Business Update
10 nov. 2021 08h30 HE | VectivBio AG
-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022- -Expanded Rare Disease Pipeline with...